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OBJECTIVE—Although the Diabetes Prevention Program (DPP) and the Finnish Diabetes
Prevention Study (FDPS) demonstrated that weight loss from lifestyle change reduces type 2
diabetesincidenceinpatientswith prediabetes,thetranslation intocommunitysettingshasbeen
difﬁcult. The objective of this study is to report the ﬁrst-year results of a community-based
translation of the DPP lifestyle weight loss (LWL) intervention on fasting glucose, insulin re-
sistance, and adiposity.
RESEARCH DESIGN AND METHODS—We randomly assigned 301 overweight and
obese volunteers (BMI 25–40 kg/m
2) with fasting blood glucose values between 95 and 125
mg/dL to a group-based translation of the DPP LWL intervention administered through a di-
abetes education program (DEP) and delivered by community health workers (CHWs) or to an
enhanced usual-care condition. CHWs were volunteers with well-controlled type 2 diabetes. A
total of 42.5% of participants were male, mean age was 57.9 years, 26% were of a race/ethnicity
other than white, and 80% reported having an education beyond high school. The primary
outcome is mean fasting glucose over 12 months of follow-up, adjusting for baseline glucose.
RESULTS—Compared with usual-care participants, LWL intervention participants experi-
encedsigniﬁcantlygreaterdecreasesinbloodglucose(24.3vs.20.4mg/dL;P,0.001),insulin
(26.5 vs. 22.7 mU/mL; P , 0.001), homeostasis model assessment of insulin resistance (21.9
vs. 20.8; P , 0.001), weight (27.1 vs. 21.4 kg; P , 0.001), BMI (22.1 vs. 20.3 kg/m
2; P ,
0.001), and waist circumference (25.9 vs. 20.8 cm; P , 0.001).
CONCLUSIONS—This translation of the DPP intervention conducted in community set-
tings, administered through a DEP, and delivered by CHWs holds great promise for the pre-
vention of diabetes by signiﬁcantly decreasing glucose, insulin, and adiposity.
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T
he Diabetes Prevention Program
(DPP) and the Finnish Diabetes Pre-
vention Study (FDPS) demonstrated
that the incidence of type 2 diabetes could
be reduced by almost 60% in patients with
prediabetes through weight loss resulting
from changes in diet and physical activity
(1,2). Despite these promising ﬁndings,
t h ep r e v a l e n c eo ft y p e2d i a b e t e sc o n t i n -
ues to increase (3). Furthermore, although
diabetes mortality has declined 8.3% in
the last decade, diabetes-related compli-
cations continue to increase, resulting in
rising disease burden (4).
Several recent translations (5–13) of
the DPP and FDPS have demonstrated en-
couragingeffectsacrossdiversesettings,in-
cluding primary care settings (6,9,11–13),
cardiac rehabilitation programs (10),
churches (8), YMCAs (5), and health care
facilities (7). The personnel who imple-
mented the intervention included nurses
(6,11,12), registered dietitians and ex-
ercise physiologists (7,10), health care
professionals (9,13), volunteer medical
personnel (8), and YMCA trainers (5).
Evaluating these translated interventions
is challenging because of the differences
in outcome measures, sample sizes, and
study designs. Although these interven-
tions typically produced ~6% weight
loss,thestudiestended tohavesmallsam-
ple sizes, often did not include compari-
son conditions, and lacked randomized
allocation to treatment conditions. No
translational study to date has reported
signiﬁcant reductions in blood glucose in
individuals with prediabetes. Therefore,
additional translational research is needed
that uses innovative, cost-effective systems
to deliver effective lifestyle interventions
targeting patients at risk for diabetes. Nu-
merousstudieshavetestedtheuseofcom-
munity health workers (CHWs) in the
managementofdiabetes(14),butnostud-
ies to date have tested the use of CHWs in
implementing lifestyle interventions de-
signed to prevent diabetes.
This report presents the ﬁrst-year re-
sults of the Healthy-Living Partnerships
to Prevent Diabetes (HELP PD) Project on
glucose, insulin resistance, and adiposity
(15). The HELP PD project was designed
to translate the methods of the DPP into
the community via key modiﬁcations to
enhance feasibility and dissemination: the
delivery of a group-based lifestyle weight
loss (LWL) intervention via a partnership




recruitment procedures, and participant
characteristics (16) have been described
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ORIGINAL ARTICLEelsewhere. In brief, the HELP PD project
is a randomized controlled trial that tests
the effect of a community-based transla-
tion of the DPP LWL intervention versus
acomparisonconditionofenhancedusual
care on fasting blood glucose, other met-
abolic outcomes, adiposity, psychosocial
variables, health-related quality of life,
and health care costs and use. Data were
collected at baseline and every 6 months
up to 24 months of follow-up. The insti-
tutional review board of Wake Forest
Baptist Medical Center approved the
study, and all participants provided
signed informed consent.
The eligibility criteria targeted a sam-
ple at risk for diabetes representative of
the local community. Recruitment (16)
was accomplished primarily through
mass mailings to targeted ZIP codes. In-
terested individuals contacted a study
telephone number and were provided
basic information about participation, in-
cluding additional steps in the screening
and randomization process and the time
commitment and expectations associated
with participation before completing a
telephone-screening questionnaire. Par-
ticipants were required to have evidence
of prediabetes on two occasions, with a
conﬁrmatory fasting glucose between 95




were screened for other comorbid condi-
tions that would make physical activity
unsafe or limit participation in the study.
These conditions included recent history
of an acute cardiovascular disease event,
clinical history of type 2 diabetes, uncon-
trolledhypertension,cancerorothercon-
ditions limiting life expectancy, chronic
use of medicines known to inﬂuence glu-
cose metabolism (i.e., corticosteroids),
and major psychiatric or cognitive prob-
lems, including depression. The Physical
Activity Readiness Questionnaire was
administered to identify people with con-
traindications to exercise, who were re-
quired to obtain a medical clearance
from their physician prior to randomiza-
tion. Participation in a supervised pro-
gram for weight loss or another research
study that would interfere with HELP PD
also was an exclusion criterion.
Outcome measures
Fasting blood glucose, insulin, and an-
thropometry were assessed at baseline and
randomizationandatthe6-and12-month
visits by trained study staff. Phlebotomy
was performed after at least an 8-h fast,
in accordance with American Diabetes
Association guidelines (18). All biochem-
ical measurements were performed in a
central laboratory by technicians masked
to the intervention assignment.
Fastingglucose,theprimaryoutcome
measure, was measured using a timed–
end point method supplied by Beckman
Coulter for the Synchron LX Analyzer, a
method accepted by the Centers for Dis-
ease Control and Prevention. Within-run
coefﬁcients of variation for this method
were #3.9% and total coefﬁcients of var-
iation were #6.45%.
Insulin was assayed using the para-
magnetic particle chemiluminescent im-
munoassay for the Access Immunoassay
Systems (Beckman Coulter). There is
,0.3% cross-reactivity with human pro-
insulin and no detectable cross-reactivity
with human C-peptide. Low- and high-
level human serum quality-control sam-
ples were run during each 24-h time
period. The overall within-assay variabil-
ity was 3.9%, and the between-assay var-
iability was 5.5%.
Insulin resistance was examined us-
ing the homeostasis model assessment of
insulin resistance (HOMA-IR) index
(HOMA IR = [{fasting insulin 3 fasting
glucose}/22.5])(19).HOMA-IRisabetter
measure of insulin resistance than is fast-
ing insulin alone and is highly correlated
with other, more complex and invasive
measures of insulin resistance from the
frequently sampled intravenous glucose
tolerance test and the euglycemic clamp
(20,19).
Anthropometric measurements were
taken with participants wearing light-
weight clothing and without shoes. Mea-
surements were taken twice during each
exam, and means were used in analyses.
Seca Accu-Hite wall-mounted stadio-
meters were used to measure height to
the nearest 0.5 cm. Weight was measured
usingaCardinalDetectodigitalscale(758
C Series) to the nearest 0.1 kg. BMI was
calculated as weight in kilograms divided
by the square of height in meters. Waist
circumferencewasassessed,tothenearest
0.1 cm, using a Gulick II 150-cm anthro-
pometric tape with the participant in a
recumbent position (21).
Community-based implementation
Our translation of the DPP involved
conducting the LWL intervention in
community-based sites via a local DEP
and CHWs. Study investigators and staff
conducted study administration, but the
registereddietitiansemployedbytheDEP
managedtheday-to-day operationsofthe
intervention as well as the training and
monitoring of the CHWs. CHWs were
community members with type 2 diabe-
tes, well-controlled HbA1c,a n dah i s t o r y
of healthy eating and physical activity.
CHWs were recruited through our DEP
by the study investigators and registered
dieticians. CHWs were responsible for
conducting the intervention group ses-
sions, managing participants, and en-
tering data on each participant’sb o d y
weights obtained at group sessions.
CHWs were compensated $100 per week
during the ﬁrst 6 months for weekly ses-
sions and $200 per month during the sec-
ond 6 months for monthly sessions. CHW
training consisted of a 36-h program con-
ducted over the course of 6–9 weeks and
involved experiential learning, didactic in-
struction, peer mentoring, and observa-
tion. Ten CHWs were trained in two
groups of ﬁve; one group before recruit-
ment started and another group 4 months
into recruitment.
LWL intervention
The LWL intervention targeted decreased
caloric intake (goal of 1,200–1,800 kcal
per day) and increased caloric expendi-
ture through moderate physical activity
(goal $180 min per week). The primary
objective was to produce a total weight
loss of 5–7% during the ﬁrst 6 months of
treatment. During the second 6 months,
participantswereencouragedtocontinue
to meet or maintain their weight loss
goals as long as their BMI did not fall be-
low 20 kg/m
2. This approach was consis-
tent with the recommendations of the
American Diabetes Association, the North
American Association for the Study of
Obesity, and the American Society for
Clinical Nutrition (22).
Participants met weekly for CHW-led
group sessions during the ﬁrst 6 months.
Fourteen different groups of 8–12 partic-
ipants were conducted at various com-
munity sites (e.g., parks and recreation
centers). Participants also received three
personalized consultations with a regis-
tered dietician (during months 1, 3, and
6). During months 7–12, participants re-
ceived two scheduled contacts with the
C H We a c hm o n t h ,o n eg r o u ps e s s i o n
and one telephone contact. Intervention
content standardization was supported
by a DVD series developed by the research
team to cover nutrition and physical ac-
tivity basics, energy balance, healthy eat-
ing,goalsetting,andproblem solving.We
also included presentations from local
community experts (e.g., the YMCA, local
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wear stores).
Enhanced usual care
The usual-care condition was designed to
exceed the usual care provided to patients
with prediabetes and to enhance reten-
tion. Usual care consisted of two individ-
ual sessions with a nutritionist during the
ﬁrst 3 months involving healthy eating
and physical activity education to support
weight loss. Usual-care participants also
received a monthly newsletter with topics
related to healthy lifestyles and informa-
tion about community resources.
Power
The HELP PD project targeted the re-
cruitment of 300 participants. The DPP
found a 4 mg/dL difference in fasting glu-
cose at 2 years. The correlation between
glucose values at baseline and follow-up
was estimated to be between 0.45 and
0.6 in two studies, with larger ranges in
baseline glucose than found in our study.
Therefore, we assumed a more modest
correlation of r = 0.2. The DPP reported
across-sectionalSDof8.3mg/dL(1).The
estimated SD for a follow-up measure
after adjusting for the baseline value is
8.3 3 the square root of (1 – 0.2
2)=
8.132. This value of the adjusted SD was
used in the NQuery program to deter-
mine sample size in a two-group trial.
The trial was designed to have at least
80–90% power to detect differences in
fasting glucose of 3–3.5 mg/dL. The re-
quired number of evaluable subjects per
group to have 80% power to detect a dif-
ference of 3 mg/dL is 117. The required
number of evaluable subjects per group
to have 90% power to detect a difference
of 3.5 mg/dL is 115. Allowing for up to
80% loss to follow-up over 2 years, the
total required number of subjects needed
to be randomly assigned to meet these
two goals is 294 and 288, respectively.
With a total sample size of 300 subjects
randomly assigned, we estimate that the
trial has 81% power to detect a 3 mg/dL
difference between groups and 91%
power to detect a 3.5 mg/dL difference.
Data analysis
Although the study was originally de-
signed with 24 months of follow-up, the
analyses reported here are based on the
ﬁrst 12 months. To compare our results
with those of other diabetes prevention
translational studies, the vast majority of
whichreport12-monthoutcomes,thein-
vestigators received approval to unblind
the ﬁrst-year results and amend the pro-
tocol to conduct independent analyses
of results in the ﬁrst and second years
of follow-up rather than the originally
plannedapproachofanalyzingthe2years
together.
Our randomization procedure in-
volved a permuted block design with
Figure 1—Flow of participants from screening to completion of the ﬁnal follow-up assessment.
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Katula and Associatesvarying block size to reduce the time
randomly assigned individuals had to
wait for intervention groups to develop
and ensure a degree of balance. Arith-
metic means and SDs are presented for
continuous variables. For baseline com-
parisons between the LWL intervention
and usual-care groups, t tests were used
for continuous variables and the Fisher
exact test was used for categorical vari-
ables. The primary hypothesis for this
report involved comparing the main ef-
fect of the LWL intervention versus the
usual-care control on fasting glucose. We
used general linear models for repeated-
measures ANCOVA (SAS PROC MIXED)
tocomparethemaineffectoftheinterven-
tion on the 6- and 12-month values mea-
sured during the 1-year follow-up period.
For each outcome measure, the baseline
value for that outcome was used as a co-
variate. The test for intervention effect is
based on the least square means of the
estimated main effect of intervention
(estimate of the average of the 6- and
12-month means). We tested for group
and visit interactions and none were sig-
niﬁcant. We used the intention-to-treat
approach and included all postrandom-
ized values according to the group to
which they were assigned. We performed
secondary analyses, making a reasonable
exception to this rule by deleting obser-
vations at visitswhere the subject wastak-
ing hypoglycemic medication. Inferences
for comparisons were tested at a 5% two-
sided level of signiﬁcance. An unstructured
variance model was used for intrasubject
longitudinal covariance.
RESULTS—The participant screening,
enrollment, and follow-up experience is
depicted in Fig. 1. The 301 participants
included a relatively well-educated, bi-
racial group of middle-aged and older
men and women with an average BMI of
32.8 kg/m
2 (Table 1). Over the ﬁrst year
of the intervention, participants attended
67.7% of all potential group intervention
sessions. Including make-up visits (either
in person or via telephone), participants
completed 79.4% of all potential ses-
sions. During the ﬁrst 6 months, 72.4%
of planned sessions were attended and
11.0% were made up with a CHW (com-
bined attendance = 83.4%). In months
7–12, 49.2% of planned sessions were at-
tended and 13.9% were made up (com-
bined attendance = 63.1%). Information
was available regarding the primary out-
come, fasting glucose, for 280 (93.4%)
participants at month 6 and 273 (90.2%)
participants at month 12, with no sub-
stantive difference in data completeness
between groups.
Table 2 displays changes in measures
of adiposity, fasting glucose, and insulin
resistance by treatment group. Relative to
usual-careparticipants,LWLintervention
participants lost a net of 6.0% of their
body weight and 5.0 cm in waist circum-
ference (P , 0.001 for both compari-
sons). Similar results were observed for
absolute weight loss and BMI. Supple-
mentary Fig. 2 illustrates changes in per-
cent weight loss over time.
On the basis of the adjusted average
of the 6- and 12-month means, fasting
glucose decreased by 4.3 mg/dL in the
LWL intervention participants versus a
decrease of 0.4 mg/dL in the usual-care
participants (P , 0.001). In secondary
analyses that examined 6- and 12-month
assessments separately, fasting glucose
had decreased by 4.0 mg/dL in the LWL
intervention versus an increase of 1.0
mg/dL in the usual-care intervention
(P , 0.001) at 6 months. At 12 months,
fasting glucose had decreased by 4.6
mg/dL in the LWL intervention versus a
decrease of 1.8 mg/dL in the usual-care
intervention (P =0 . 0 2 ) .R e l a t i v et ou s u a l -
care participants, LWL intervention par-
ticipants also demonstrated substantial
decreases in fasting insulin and HOMA-
IR (P , 0.001 for both comparisons).
Supplementary Table A1 contains
data on adverse events, serious adverse
events, and the number of new cases of
diabetes by treatment group. No differ-
ences were found in these events between
treatment groups.
CONCLUSIONS—These results indi-
cate that the HELP PD project was suc-
cessful in translating the DPP LWL
intervention into a community-based ap-
proach that induced signiﬁcant reductions
in blood glucose, insulin, HOMA-IR, body
weight, waist circumference, and BMI over
12 months in overweight and obese pa-
tients with prediabetes.Toour knowledge,
this study is the largest to date to success-
fullytranslatetheDPPintothecommunity
and is the only DPP translational study to
document signiﬁcant changes in fasting
blood glucose, insulin, and insulin resis-
tance using a randomized controlled de-
sign.
The glucose-lowering effect of the
HELP PD intervention compares favor-
ably with the effects documented in the
DPP and FDPS (24a n d25m g / d L ,r e -
spectively, albeit over longer follow-up
periods [DPP follow-up = 2.8 years and
FDPS follow-up = 3.2 years]). Our future
analyseswillexaminethe sustainability of
the HELP PD effect over 24 months. The
effect of the HELP PD intervention on ad-
iposity also compares favorably to other
studies.Areview(23)ofninerandomized
controlled trials examining weight loss
Table 1—Baseline sample characteristics
Variable LWL intervention Usual care Total P*
n 151 150 301
Sex 1.00
Male 64 (42.4) 64 (42.7) 128 (42.5)
Female 87 (57.6) 86 (57.3) 173 (57.5)
Race 0.37
African American 39 (25.8) 35 (23.3) 74 (24.7)
White 111 (73.5) 111 (74.0) 222 (74.0)
Other 1 (0.70) 4 (2.7) 4 (1.3)
Age (years) 57.3 6 10.1 58.5 6 9.0 57.9 6 9.5 0.28
Educational attainment 0.96
High school or less 29 (19.2) 31 (21.3) 61 (20.3)
Associate degree or other 37 (24.5) 37 (24.7) 97 (32.2)
Bachelor’s degree 37 (24.5) 37 (24.7) 74 (24.6)
Beyond Bachelor’s degree 45 (31.8) 44 (29.3) 69 (22.9)
Weight (kg) 94.38 6 14.7 93.0 6 16.2 94.1 6 15.6 0.44
BMI (kg/m
2) 32.8 6 3.9 32.6 6 4.1 32.7 6 4.0 0.54
Glucose (mg/dL) 105.4 6 12.5 105.7 6 10.0 105.5 6 11.3 0.79
Insulin (mU/mL) 16.7 6 9.7 16.7 6 10.0 16.7 6 9.8 0.95
HOMA-IR 4.4 6 3.0 4.4 6 2.9 4.4 6 2.9 0.99
Data are n (%) or means 6 SD. *t Tests were used for continuous variables and the Fisher exact test was used
for categorical variables.
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diabetes reported a pooled estimate of
22.8 kg of weight loss (23.3% of ini-
tial body weight) calculated from four
studies with 1 year of follow-up. The
DPP (1) and FDPS (2) reported weight
loss of 25.5 kg (24.9%) and 24.2 kg
(24.7%), respectively. In addition, the
DPP documented a weight loss of
26.0 kg at 12 months of follow-up. Par-
ticipants in the HELP PD LWL interven-
tion lost an average of 27.1 kg (7.3%) at
12 months. However, trials consistently
show that approximately one-third of
the weight lost during the ﬁrst 6 months
of behavioral weight loss interventions is
typically regained by 1 year, and weight
returns to baseline in 3–5 years (24).Our
future analyses will determine whether
weight loss is sustained over 24 months
of follow-up.
Previous diabetes prevention transla-
tional studies have reported 12-month
weight losses ranging from 20.45 kg (8)
to 25.7 kg (5), but other than Boltri
et al. (8), none have reported signiﬁcant
changes in fasting blood glucose. The
DEPLOY (Diabetes Education and Pre-
v e n t i o nw i t haL i f e s t y l eI n t e r v e n t i o nO f -
fered at the YMCA) study (5) delivered a
group-based translation of the DPP LWL
interventionviaYMCAsto77participants
with elevated glucose and reported sig-
niﬁcant decreases in weight (25.7 kg)
and BMI (26.7%) but no differences
between groups in changes in cardiome-
tabolic outcomes (e.g., HbA1c). Likewise,
the Weight Loss through Living Well
(WiLLoW) study (11), using a non-
randomized controlled cohort design,
delivered a group-based DPP LWL in-
tervention to overweight patients via
primary care practices and reported a
1 2 - m o n t hw e i g h tc h a n g eo f–5.7 kg but
didnotreportchangesincardiometabolic
outcomes. Kramer et al (9) assessed the
impact of a group-based DPP LWL inter-
ventioninpatientsatrisk fordiabetes(n=
42) delivered via primary care practices
using a one-group design and reported
signiﬁcant 12-month changes in weight
(24.2 kg [24.5%]), waist circumference
(27.1 cm [26.8%]), and BMI (21.6
[24.8%]), but changes in glucose (21.5
mg/dL [21.4%]) were not signiﬁcant.
At a national level, Saaristo et al. (13) im-
plemented the FDPS lifestyle interven-
tion in 2,798 individuals with elevated
risk for diabetes in 400 primary care set-
tings and reported a mean of 21.2 kg of
weight loss. Although this study did not
report changes in fasting glucose, the re-
sults indicate that the reduction in inci-
dence of diabetes (assessed using an oral
glucose tolerance test) was strongly re-
lated to weight loss (relative risk of diabe-
tes was 0.31 in the group who lost 5%
weight, 0.72 in the group who lost 2.5–
4.9% weight, and 1.10 in the group who
gained 2.5% compared with the group
who maintained weight). The results pre-
sented here suggest that the HELP PD
projectapproachmay beamorepowerful
translation of the DPP than previously
published approaches.
Table 2—Measures of adiposity and metabolic outcomes of HELP PD at 6 and 12 months by treatment group
Variable Baseline 6 months 12 months
Adjusted means over
the follow-up period* P
Weight (lb)
Control group 92.67 6 1.37 91.55 6 1.38 90.93 6 1.37 92.12 6 0.29
Intervention group 94.41 6 1.24 87.14 6 1.22 87.44 6 1.28 86.39 6 0.30
Difference 25.73 6 0.42 ,0.001
BMI (kg/m
2)
Control group 32.42 6 0.35 31.96 6 0.34 31.95 6 0.36 32.15 6 0.10
Intervention group 32.81 6 0.34 30.38 6 0.35 30.52 6 0.36 30.25 6 0.10
Difference 21.90 6 0.14 ,0.001
Waist (cm)
Control group 104.22 6 0.91 103.37 6 0.90 103.45 6 0.89 103.70 6 0.27
Intervention group 104.83 6 0.79 98.67 6 0.84 99.22 6 0.90 98.65 6 0.27
Difference 25.05 6 0.38 ,0.001
Glucose (mg/dL)
Control group 105.92 6 0.83 106.97 6 0.77 104.16 6 0.99 105.36 6 0.53
Intervention group 105.58 6 1.07 101.69 6 0.81 101.11 6 0.84 101.60 6 0.54
Difference 23.76 6 0.76 ,0.001
Insulin (mU/mL)
Control group 16.92 6 0.84 15.54 6 1.07 12.81 6 0.64 14.09 6 0.41
Intervention group 16.73 6 0.82 10.73 6 0.61 9.76 6 0.46 10.34 6 0.41
Difference 23.75 6 0.58 ,0.001
HOMA-IR
Control group 4.50 6 0.24 4.18 6 0.30 3.33 6 0.18 3.73 6 0.12
Intervention group 4.48 6 0.26 2.77 6 0.18 2.48 6 0.13 2.65 6 0.12
Difference 21.08 6 0.17 ,0.001
Percentage weight loss
Control group 0.00 6 0.00 21.18 6 0.29 21.33 6 0.39 21.25 6 0.31
Intervention group 0.00 6 0.00 27.52 6 0.48 27.21 6 0.57 27.37 6 0.31
Difference 26.11 6 0.44 ,0.001
Data are means 6 SE. *Least square means from a repeated-measures ANCOVA using the baseline value as a covariate; P values represent the between-group
comparison of the average of the 6- and 12-month means.
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Katula and AssociatesFasting insulin and HOMA-IR, two
measures of insulin resistance, responded
favorably to the intervention. Insulin re-
sistance is a key link between obesity and
the risk of both diabetes and cardiovas-
cular disease (25). The beneﬁcial effects
on insulin resistance provide support for
the hypothesis that the intervention may
have beneﬁcial effects on the risk for car-
diovascular disease beyond the effects on
blood glucose.
The HELP PD project made several
keymodiﬁcationstotheDPPintervention
to create a model that can be translated
foruseinanycommunitywithaDEP.The
intervention was delivered in a group
format by CHWs in community-based
settings and was overseen by registered
dieticians employed by a local DEP,
thereby minimizing the contributions of
research resources and maximizing the
responsibilitiesofcommunity-basedstaff.
The results of the current study indicate
that this model is effective at inducing
meaningful metabolic changes in individ-
uals at high risk for diabetes.
Although the .3,000 American Dia-
betes Association–recognized DEPs in
the U.S. are well positioned to implement
thisintervention,severallimitationsexist.
First,theHELPPDprojectwasconducted
in only one community located in the
southeastern U.S. It is unknown whether
this approach can be effectively dissemi-
nated to other communities. In addition,
a training program must be developed to
prepare personnel. Finally, reimburse-
ment policies must be developed to
support the cost of program delivery.
Economic analysis of the HELP PD pro-
gram is underway and may help inform
policy development. Despite these limita-
tions,the resultsoftheHELPPDprogram
indicate that empowering community
members through partnerships with ex-
isting DEPs may effectively translate dia-
betes prevention efforts and ultimately
alterthecourseoftheobesityanddiabetes
epidemics.
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